SAFETY DATA SHEET

Ezetimibe / Atorvastatin Formulation

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name: Ezetimibe / Atorvastatin Formulation

Manufacturer or supplier’s details
Company name of supplier: MSD
Address: Avenida 16 de Septiembre No. 301
Xaltocan - Xochimilco Mexico 16090
Telephone: 52 55 57284444
Telefax: 908-735-1496
Emergency telephone: 1-908-423-6000
E-mail address: EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use: Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification
Specific target organ toxicity - repeated exposure (Oral): Category 2 (Liver, muscle)

GHS label elements
Signal Word: Warning

Hazard Statements: H373 May cause damage to organs (Liver, muscle) through prolonged or repeated exposure if swallowed.

Precautionary Statements: Prevention:
P260 Do not breathe dust.

Response:
P314 Get medical advice/ attention if you feel unwell.

Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture: Mixture

Components
SECTION 4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air. Get medical attention if symptoms occur.

In case of skin contact: Wash with water and soap. Get medical attention if symptoms occur.

In case of eye contact: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed: May cause damage to organs through prolonged or repeated exposure if swallowed. Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during firefighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides
Nitrogen oxides (NOx)
Fluorine compounds
Metal oxides

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so.
### SECTION 6. ACCIDENTAL RELEASE MEASURES

| Personal precautions, protective equipment and emergency procedures | : Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations. |
| Environmental precautions | : Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained. |
| Methods and materials for containment and cleaning up | : Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements. |

### SECTION 7. HANDLING AND STORAGE

| Technical measures | : Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres. |
| Local/Total ventilation | : Use only with adequate ventilation. |
| Advice on safe handling | : Do not breathe dust. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures | : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. |
When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

**Conditions for safe storage**: Keep in properly labeled containers. Store in accordance with the particular national regulations.

**Materials to avoid**: Do not store with the following product types: Strong oxidizing agents

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>VLE-PPT</td>
<td>10 mg/m³</td>
<td>NOM-010-STPS-2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Atorvastatin</td>
<td>134523-03-8</td>
<td>TWA</td>
<td>0.05 mg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>0.5 mg/100 cm²</td>
<td>Internal</td>
</tr>
<tr>
<td>Ezetimibe</td>
<td>163222-33-1</td>
<td>TWA</td>
<td>25 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>250 µg/100 cm²</td>
<td>Internal</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>VLE-PPT</td>
<td>10 mg/m³</td>
<td>NOM-010-STPS-2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Inhalable fraction)</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Respirable fraction)</td>
<td>3 mg/m³</td>
<td>ACGIH</td>
</tr>
</tbody>
</table>

**Engineering measures**: All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

**Personal protective equipment**

**Respiratory protection**: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. **Filter type**: Particulates type

**Hand protection**

**Material**

Chemical-resistant gloves
Remarks: Consider double gloving.

Eye protection: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance</td>
<td>powder</td>
</tr>
<tr>
<td>Color</td>
<td>off-white</td>
</tr>
<tr>
<td>Odor</td>
<td>No data available</td>
</tr>
<tr>
<td>Odor Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>pH</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>No data available</td>
</tr>
<tr>
<td>Initial boiling point and boiling range</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash point</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Evaporation rate</td>
<td>No data available</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>May form explosive dust-air mixture during processing, handling or other means.</td>
</tr>
<tr>
<td>Flammability (liquids)</td>
<td>No data available</td>
</tr>
<tr>
<td>Upper explosion limit / Upper flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower explosion limit / Lower flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapor pressure</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative vapor density</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative density</td>
<td>No data available</td>
</tr>
<tr>
<td>Density</td>
<td>No data available</td>
</tr>
<tr>
<td>Solubility(ies)</td>
<td></td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET

Ezetimibe / Atorvastatin Formulation

Version: 4.3
Revision Date: 09/13/2019
SDS Number: 26495-00013
Date of last issue: 24.04.2019
Date of first issue: 29.10.2014

Water solubility: 0.01 g/l
Partition coefficient: n-octanol/water: No data available
Autoignition temperature: No data available
Decomposition temperature: No data available
Viscosity
Viscosity, kinematic: No data available
Explosive properties: Not explosive
Oxidizing properties: The substance or mixture is not classified as oxidizing.
Molecular weight: No data available
Particle size: No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions:
- May form explosive dust-air mixture during processing, handling or other means.
- Can react with strong oxidizing agents.
Conditions to avoid: Heat, flames and sparks.
Incompatible materials: Oxidizing agents
Hazardous decomposition products: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure
Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Components:

Cellulose:
Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity: LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
**Acute dermal toxicity**

: LD50 (Rabbit): > 2,000 mg/kg

**Atorvastatin:**

- **Acute oral toxicity**
  : LD50 (Rat, male and female): > 5,000 mg/kg
  
  : LD50 (Mouse, male and female): > 5,000 mg/kg

- **Acute inhalation toxicity**
  : Remarks: No data available

- **Acute dermal toxicity**
  : Remarks: No data available

**Ezetimibe:**

- **Acute oral toxicity**
  : LD50 (Rat): > 5,000 mg/kg
  
  : LD50 (Mouse): > 5,000 mg/kg
  
  : LD50 (Dog): > 3,000 mg/kg

- **Acute inhalation toxicity**
  : Remarks: No data available

**Magnesium stearate:**

- **Acute oral toxicity**
  : LD50 (Rat): > 2,000 mg/kg
  
  : Method: OECD Test Guideline 423
  
  : Assessment: The substance or mixture has no acute oral toxicity
  
  : Remarks: Based on data from similar materials

- **Acute dermal toxicity**
  : LD50 (Rabbit): > 2,000 mg/kg
  
  : Remarks: Based on data from similar materials

**Skin corrosion/irritation**

Not classified based on available information.

**Components:**

**Atorvastatin:**

- **Species**: Rabbit
  
  : Result: No skin irritation

**Ezetimibe:**

- **Species**: Rabbit
  
  : Result: No skin irritation

**Magnesium stearate:**

- **Species**: Rabbit
  
  : Result: No skin irritation
  
  : Remarks: Based on data from similar materials
**SAFETY DATA SHEET**

**Ezetimibe / Atorvastatin Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
</table>

**Serious eye damage/eye irritation**
Not classified based on available information.

**Components:**

**Atorvastatin:**
- **Species**: Rabbit
- **Result**: No eye irritation
- **Method**: Draize Test

**Ezetimibe:**
- **Species**: Rabbit
- **Result**: No eye irritation

**Magnesium stearate:**
- **Species**: Rabbit
- **Result**: No eye irritation
- **Remarks**: Based on data from similar materials

**Respiratory or skin sensitization**

**Skin sensitization**
Not classified based on available information.

**Respiratory sensitization**
Not classified based on available information.

**Components:**

**Atorvastatin:**
- **Test Type**: Maximization Test
- **Routes of exposure**: Skin contact
- **Species**: Guinea pig
- **Result**: negative

**Ezetimibe:**
- **Test Type**: Maximization Test
- **Species**: Guinea pig
- **Result**: negative

**Magnesium stearate:**
- **Test Type**: Maximization Test
- **Routes of exposure**: Skin contact
- **Species**: Guinea pig
- **Method**: OECD Test Guideline 406
- **Result**: negative
- **Remarks**: Based on data from similar materials

**Germ cell mutagenicity**
Not classified based on available information.
## Components:

### Cellulose:

**Genotoxicity in vitro**
- Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative
- Test Type: In vitro mammalian cell gene mutation test
  - Result: negative

**Genotoxicity in vivo**
- Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  - Species: Mouse
  - Application Route: Ingestion
  - Result: negative

### Atorvastatin:

**Genotoxicity in vitro**
- Test Type: reverse mutation assay
  - Test system: Salmonella typhimurium
  - Result: negative
- Test Type: reverse mutation assay
  - Test system: Escherichia coli
  - Result: negative
- Test Type: In vitro mammalian cell gene mutation test
  - Test system: Chinese hamster lung cells
  - Result: negative
- Test Type: sister chromatid exchange assay
  - Test system: Chinese hamster lung cells
  - Result: negative

**Genotoxicity in vivo**
- Test Type: In vivo micronucleus test
  - Species: Mouse
  - Cell type: Bone marrow
  - Application Route: Oral
  - Result: negative

### Ezetimibe:

**Genotoxicity in vitro**
- Test Type: Bacterial reverse mutation assay (AMES)
  - Metabolic activation: with and without metabolic activation
  - Result: negative
- Test Type: Chromosomal aberration
  - Test system: Human lymphocytes
  - Result: negative

**Genotoxicity in vivo**
- Test Type: Micronucleus test
  - Species: Mouse
  - Cell type: Bone marrow
  - Application Route: Oral
  - Result: negative
Magnesium stearate:
Genotoxicity in vitro:
- Test Type: In vitro mammalian cell gene mutation test
  - Result: negative
  - Remarks: Based on data from similar materials
- Test Type: Chromosome aberration test in vitro
  - Method: OECD Test Guideline 473
  - Result: negative
  - Remarks: Based on data from similar materials
- Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative
  - Remarks: Based on data from similar materials

Carcinogenicity
Not classified based on available information.

Components:

Cellulose:
- Species: Rat
- Application Route: Ingestion
- Exposure time: 72 weeks
- Result: negative

Atorvastatin:
- Species: Mouse, male and female
- Application Route: oral (gavage)
- Exposure time: 2 Years
- NOAEL: 200 mg/kg body weight
- LOAEL: 400 mg/kg body weight
- Result: negative
- Target Organs: Liver
- Species: Rat, female
- Application Route: oral (gavage)
- Exposure time: 2 Years
- LOAEL: 100 mg/kg body weight
- Target Organs: Musculo-skeletal system

Ezetimibe:
- Species: Rat, female
- Application Route: oral (feed)
- Exposure time: 104 weeks
- Result: negative
- Species: Rat, male
- Application Route: oral (feed)
- Exposure time: 104 weeks
- Result: negative
- Species: Mouse
- Application Route: oral (feed)
Exposure time: 104 weeks
Result: negative

Reproductive toxicity
Not classified based on available information.

Components:

Cellulose:
Effects on fertility: Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on fetal development: Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative

Atorvastatin:
Effects on fertility: Test Type: Fertility/early embryonic development
Species: Rat, female
Fertility: NOAEL: 225 mg/kg body weight
Result: No effects on fertility.

Test Type: Fertility/early embryonic development
Species: Rat, male
Fertility: NOAEL: 175 mg/kg body weight
Result: No effects on fertility.

Effects on fetal development: Species: Rat, female
Developmental Toxicity: NOAEL: 20 mg/kg body weight
Result: No teratogenic effects., Embryo-fetal toxicity.
Remarks: Maternal toxicity observed.

Species: Rabbit, female
Application Route: Oral
Developmental Toxicity: NOAEL: 100 mg/kg body weight
Result: No embryo-fetal toxicity.

Ezetimibe:
Effects on fertility: Test Type: Fertility/early embryonic development
Species: Rat, male and female
Fertility: NOAEL: > 1,000 mg/kg body weight
Result: No effects on fertility., No fetotoxicity.

Effects on fetal development: Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: > 1,000 mg/kg body weight
Result: No adverse effects.
Magnesium stearate:
Effects on fertility:
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: > 1,000 mg/kg body weight
Result: No adverse effects.

Effects on fetal development:
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative
Remarks: Based on data from similar materials

STOT-single exposure
Not classified based on available information.

STOT-repeated exposure
May cause damage to organs (Liver, muscle) through prolonged or repeated exposure if swallowed.

Components:

Atorvastatin:
Routes of exposure: Ingestion
Target Organs: Liver, muscle
Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Cellulose:
Species: Rat
NOAEL: >= 9,000 mg/kg
Application Route: Ingestion
Exposure time: 90 Days

Atorvastatin:
Species: Rat, male and female
LOAEL: 70 mg/kg
Application Route: oral (gavage)
Exposure time: 52 Weeks
Target Organs: Liver
Species: Dog
LOAEL: 10 mg/kg  
Application Route: oral (gavage)  
Exposure time: 104 Weeks  
Target Organs: Liver

Ezetimibe:
Species: Dog  
NOAEL: 1,000 mg/kg  
Application Route: Oral  
Exposure time: 90 d  
Remarks: No significant adverse effects were reported

Species: Rat  
NOAEL: 1,500 mg/kg  
Application Route: Oral  
Exposure time: 90 d  
Remarks: No significant adverse effects were reported

Species: Mouse  
NOAEL: 500 mg/kg  
Application Route: Oral  
Exposure time: 90 d  
Remarks: No significant adverse effects were reported

Species: Dog  
NOAEL: 300 mg/kg  
Application Route: Oral  
Exposure time: 1 y  
Remarks: No significant adverse effects were reported

Magnesium stearate:
Species: Rat  
NOAEL: > 100 mg/kg  
Application Route: Ingestion  
Exposure time: 90 Days  
Remarks: Based on data from similar materials

Aspiration toxicity
Not classified based on available information.

Components:
Ezetimibe:
Not applicable

Experience with human exposure

Components:
Atorvastatin:
Ingestion: Symptoms: muscle pain, Fatigue, stomach discomfort, Abdominal pain, constipation, flatulence, liver function change
Ezetimibe:
Ingestion: Symptoms: Headache, Nausea, Vomiting, Diarrhea, flatulence, muscle pain, upper respiratory tract infection, Back pain, joint pain

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Cellulose:
Toxicity to fish: LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

Atorvastatin:
Toxicity to fish: LC50 (Pimephales promelas (fathead minnow)): > 92 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 200 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants: EC50 (Pseudokirchneriella subcapitata (green algae)): 108 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 14 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity): NOEC (Pimephales promelas (fathead minnow)): 0.49 mg/l
Exposure time: 33 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity): NOEC (Daphnia magna (Water flea)): 0.2 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms: EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition

Ezetimibe:
Toxicity to fish: LC50 (Pimephales promelas (fathead minnow)): > 0.125 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
Remarks: No toxicity at the limit of solubility.
Toxicity to daphnia and other aquatic invertebrates:
- EC50 (Daphnia magna (Water flea)): > 4 mg/l
  Exposure time: 48 h
  Method: OECD Test Guideline 202
  Remarks: No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants:
- EC50 (Pseudokirchneriella subcapitata (green algae)): > 0.317 mg/l
  Exposure time: 96 h
  Method: OECD Test Guideline 201
  Remarks: No toxicity at the limit of solubility.

  NOEC (Pseudokirchneriella subcapitata (green algae)): 0.317 mg/l
  Exposure time: 96 h
  Method: OECD Test Guideline 201
  Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic toxicity):
- NOEC (Pimephales promelas (fathead minnow)): 0.051 mg/l
  Exposure time: 33 d
  Method: OECD Test Guideline 210

- NOEC (Cyprinodon variegatus (sheepshead minnow)): 4 mg/l
  Exposure time: 7 d
  Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):
- NOEC (Daphnia magna (Water flea)): 0.282 mg/l
  Exposure time: 21 d
  Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms:
- EC50: > 4.4 mg/l
  Exposure time: 3 h
  Test Type: Respiration inhibition
  Method: OECD Test Guideline 209
  Remarks: No toxicity at the limit of solubility.

  NOEC: 4.4 mg/l
  Exposure time: 3 h
  Test Type: Respiration inhibition
  Method: OECD Test Guideline 209
  Remarks: No toxicity at the limit of solubility.

Magnesium stearate:
Toxicity to fish:
- LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l
  Exposure time: 48 h
  Method: DIN 38412
  Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates:
- EL50 (Daphnia magna (Water flea)): > 1 mg/l
  Exposure time: 47 h
  Test substance: Water Accommodated Fraction
  Remarks: Based on data from similar materials
  No toxicity at the limit of solubility.
Toxicity to algae/aquatic plants:

- EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
  Exposure time: 72 h
  Test substance: Water Accommodated Fraction
  Method: OECD Test Guideline 201
  Remarks: Based on data from similar materials
  No toxicity at the limit of solubility.

- NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
  Exposure time: 72 h
  Test substance: Water Accommodated Fraction
  Method: OECD Test Guideline 201
  Remarks: Based on data from similar materials

Toxicity to microorganisms:

- EC10 (Pseudomonas putida): > 100 mg/l
  Exposure time: 16 h
  Test substance: Water Accommodated Fraction
  Remarks: Based on data from similar materials

Persistence and degradability

**Components:**

**Cellulose:**
- Biodegradability: Result: Readily biodegradable.

**Atorvastatin:**
- Biodegradability: Result: Not readily biodegradable.
  Biodegradation: 7.7 %
  Exposure time: 28 d
  Method: OECD Test Guideline 314

**Ezetimibe:**
- Biodegradability: Result: Not readily biodegradable.
  Biodegradation: 6.8 %
  Exposure time: 28 d

Stability in water:
- Hydrolysis: 50 % (4.5 d)
  Method: OECD Test Guideline 111

**Magnesium stearate:**
- Biodegradability: Result: Not biodegradable.
  Remarks: Based on data from similar materials

Bioaccumulative potential

**Components:**

**Atorvastatin:**
- Partition coefficient: n-octanol/water: log Pow: 1.62
Ezetimibe: Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)  
Bioconcentration factor (BCF): 173  
Exposure time: 97 d  
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.36

Magnesium stearate:  
Partition coefficient: n-octanol/water : log Pow: > 4

Mobility in soil

Components:

Atorvastatin:  
Distribution among environmental compartments : log Koc: 2.84

Ezetimibe:  
Distribution among environmental compartments : log Koc: 4.35  
Method: OECD Test Guideline 106

Other adverse effects  
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods  
Waste from residues : Dispose of in accordance with local regulations.  
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.
SAFETY DATA SHEET

Ezetimibe / Atorvastatin Formulation

Version: 4.3
Revision Date: 09/13/2019
SDS Number: 26495-00013
Date of last issue: 24.04.2019
Date of first issue: 29.10.2014

Labels: Miscellaneous
Packing instruction (cargo aircraft): 956
Packing instruction (passenger aircraft): 956
Environmentally hazardous: yes

IMDG-Code
UN number: UN 3077
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Atorvastatin)

Class: 9
Packing group: III
Labels: 9
EmS Code: F-A, S-F
Marine pollutant: yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation

NOM-002-SCT
UN number: UN 3077
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Atorvastatin)

Class: 9
Packing group: III
Labels: 9

Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture
Federal Law for the control of chemical precursors, essential chemical products and machinery for producing capsules, tablets and pills: Not applicable

The ingredients of this product are reported in the following inventories:
AICS: not determined
DSL: not determined
IECSC: not determined
### SECTION 16. OTHER INFORMATION

**Full text of other abbreviations**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACGIH</td>
<td>USA. ACGIH Threshold Limit Values (TLV)</td>
</tr>
<tr>
<td>NOM-010-STPS-2014</td>
<td>Mexico. Norm NOM-010-STPS-2014 on Chemicals Polluting the Work Environment - Identification, Assessment and Control - Appendix 1 Occupational Exposure Limits</td>
</tr>
<tr>
<td>ACGIH / TWA</td>
<td>8-hour, time-weighted average</td>
</tr>
<tr>
<td>NOM-010-STPS-2014 / VLE-PPT</td>
<td>Time weighted average limit value</td>
</tr>
</tbody>
</table>

**Sources of key data used to compile the Material Safety Data Sheet**


**Revision Date**

- 09/13/2019

The information is considered as correct, but not exhaustive, and will be used only as a guide, which is based in the current knowledge of the substance or mixture, and is applicable to proper safety precautions for the product.